Acute kidney injury (AKI) is a frequent complication of multiple myeloma and is due predominantly to paraprotein-mediated nephrotoxicity. AKI occurs in myeloma patients due to a number of causes, including prerenal azotemia, metabolic nephrotoxicity from hypercalcemia and tumor lysis syndrome, proximal tubular injury, cast nephropathy, and drug-related nephrotoxicity. Importantly, AKI may develop in patients with known multiple myeloma or as an initial manifestation of this monoclonal disease. Diagnostic work-up includes the demonstration of monoclonal proteins, the search for the underlying B-cell clone, and a kidney biopsy, in many instances. Myeloma management involves treatment with chemotherapeutic agents to rapidly lower light chain levels, along with supportive measures that optimize volume status, correct metabolic disturbances, reduce proteinuria, and minimize nephrotoxin exposure. Extracorporeal therapies, such as plasma exchange and high-cutoff hemodialysis, have been employed, but their utility remain uncertain. The presence of AKI in myeloma patients appears to be associated with a higher mortality. Partial and full renal recovery are associated with better survival.
SalahudeenAKDoshiSMPawarTNowshadGLahotiAShahPIncidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin J Am Soc Nephrol2013; 8(3): 347–354
2.
de MendonçaAVincentJLSuterPMet al.Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med2000; 26(7): 915–921
3.
KnudsenLMHjorthMHippeENordic Myeloma Study Group. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Eur J Haematol2000; 65(3): 175–181
4.
KnudsenLMHippeEHjorthMHolmbergEWestinJThe Nordic Myeloma Study Group. Renal function in newly diagnosed multiple myelomaa demographic study of 1353 patients. Eur J Haematol1994; 53(4): 207–212
5.
International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol2003; 121(5): 749–757
6.
KatzmannJAKyleRABensonJet al.Screening panels for detection of monoclonal gammopathies. Clin Chem2009; 55(8): 1517–1522
7.
HutchisonCAPlantTDraysonMet al.Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol2008; 9(11https://link.springer.com/article/10.1186/1471-2369-9-11. Accessed August 30, 2017.
8.
JacobsonJLHusseinMABarlogieBDurieBGCrowleyJJSouthwest Oncology Group. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol2003; 122(3): 441–450
9.
DraysonMBegumGBasuSet al.Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood2006; 108(6): 2013–2019
10.
BasnayakeKStringerSJHutchisonCACockwellPThe biology of immunoglobulin free light chains and kidney injury. Kidney Int2011; 79(12): 1289–1301
11.
DoshiMLahotiADaneshFRBatumanVSandersPWAmerican Society of Nephrology Onco-Nephrology Forum. Paraprotein-Related Kidney Disease: Kidney Injury from Paraproteins-What Determines the Site of Injury? Clin J Am Soc Nephrol2016; 11(12): 2288–2294
12.
SandersPWBookerBBPathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest1992; 89(2): 630–639
13.
StewartAFClinical practice. Hypercalcemia associated with cancer. N Engl J Med2005; 352(4): 373–379
14.
OyajobiBOMundyGRPathophysiology of myeloma bone disease. Multiple Myeloma and Related Disorders2004274–88
DenoroyLDéretSAucouturierPOverrepresentation of the V kappa IV subgroup in light chain deposition disease. Immunol Lett1994; 42(1-2): 63–66
18.
ZhuLHerreraGAMurphy-UllrichJEHuangZQSandersPWPathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor-beta. Am J Pathol1995; 147(2): 375–385
19.
HerreraGARenal manifestations of plasma cell dyscrasias: an appraisal from the patients bedside to the research laboratory. Ann Diagn Pathol2000; 4(3): 174–200
20.
KambhamNMarkowitzGSAppelGBKleinerMJAucouturierPDagatiVDHeavy chain deposition disease: the disease spectrum. Am J Kidney Dis1999; 33(5): 954–962
21.
AuphanNDiDonatoJARosetteCHelmbergAKarinMImmunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science1995; 270(5234): 286–290
22.
RayALaForgeKSSehgalPBOn the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol1990; 10(11): 5736–5746
23.
WanchooRAbudayyehADoshiMet al.Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. Clin J Am Soc Nephrol2017; 12(1): 176–189
24.
DimopoulosMARichardsonPGSchlagRet al.VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol2009; 27(36): 6086–6093
25.
SinghalSMehtaJDesikanRet al.Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med1999; 341(21): 1565–1571
26.
SaidSMSethiSValeriAMet al.Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol2013; 8(9): 1515–1523
27.
KeelingJTengJHerreraGAAL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest2004; 84(10): 1322–1338
28.
LeungNNasrSHSethiSHow I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. Blood2012; 120(16): 3206–3213
29.
SirohiBPowlesRHarousseauJLAndersonKCThe evolving background for high-dose treatment for myeloma. Bone Marrow Transplant2007; 40(12): 1097–1100
30.
HarousseauJLMoreauPAutologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med2009; 360(25): 2645–2654
31.
St BernardRChodirkerLMasih-KhanEet al.Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplant2015; 50(1): 95–99
32.
ParikhGCAmjadAISalibaRMet al.Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant2009; 15(7): 812–816
33.
ZagerRAAcute renal failure in the setting of bone marrow transplantation. Kidney Int1994; 46(5): 1443–1458
34.
KerstingSKoomansHAHenéRJVerdonckLFAcute renal failure after allogeneic myeloablative stem cell transplantation: retrospective analysis of incidence, risk factors and survival. Bone Marrow Transplant2007; 39(6): 359–365
35.
SandersPWMechanisms of light chain injury along the tubular nephron. J Am Soc Nephrol2012; 23(11): 1777–1781
36.
StokesMBValeriAMHerlitzLet al.Light Chain Proximal Tubulopathy: Clinical and Pathologic Characteristics in the Modern Treatment Era. J Am Soc Nephrol2016; 27(5): 1555–1565
37.
LeboulleuxMLelongtBMougenotBet al.Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int1995; 48(1): 72–79
38.
TannerGAKnoppLCGlomerular blood flow after single nephron obstruction in the rat kidney. Am J Physiol1986; 250(1 Pt 2): F77–F85
39.
KorbetSMSchwartzMMMultiple myeloma. J Am Soc Nephrol2006; 17(9): 2533–2545
40.
YadavPCookMCockwellPCurrent Trends of Renal Impairment in Multiple Myeloma. Kidney Dis (Basel)2016; 1(4): 241–257
41.
HutchisonCACockwellPStringerSet al.Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol2011; 22(6): 1129–1136
42.
LeungNGertzMAZeldenrustSRet al.Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int2008; 73(11): 1282–1288
43.
ClarkWFStewartAKRockGAet al.Canadian Apheresis Group. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med2005; 143(11): 777–784
44.
BurnetteBLLeungNRajkumarSVRenal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med2011; 364(24): 2365–2366
45.
HutchisonCAHeyneNAiriaPet al.Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant2012; 27(10): 3823–3828
46.
PerazellaMAMoeckelGWNephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol2010; 30(6): 570–581
47.
MarkowitzGSAppelGBFinePLet al.Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol2001; 12(6): 1164–1172
48.
MarkowitzGSFinePLStackJIet al.Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int2003; 64(1): 281–289
49.
MehtaNSaxenaANiesvizkyRBortezomib-induced thrombotic thrombocytopaenic purpura. BMJ Case Rep2012201210.1136/bcr-2012-006461.
50.
MoritaRHashinoSShiraiSet al.Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma. Int J Hematol2008; 88(2): 248–250
HarrisEBehrensJSamsonDRahemtullaARussellNHByrneJLUse of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol2003; 122(1): 160–161
55.
GlezermanIGKewalramaniTJhaveriKReversible Fanconi syndrome due to lenalidomide. NDT Plus2008; 1(4): 215–217
56.
ShaabanHLayneTGuronGA case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide. J Oncol Pharm Pract2014; 20(4): 302–304
57.
JammeMGalichonPHertigAMinimal change disease and lenalidomide. Am J Kidney Dis2013; 62(4): 844
58.
BairdPLeungSHoangHet al.A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use. J Oncol Pharm Pract2016; 22(2): 357–360
59.
NasrSHValeriAMSethiSet al.Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis2012; 59(6): 786–794
60.
ZandLNasrSHGertzMAet al.Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leuk Lymphoma2015; 56(12): 3357–3364
61.
NasrSHValeriAMCornellLDet al.Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol2012; 7(2): 231–239
62.
NasrSHSaidSMValeriAMet al.The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int2013; 83(3): 463–470
63.
KastritisEAnagnostopoulosARoussouMet al.Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica2007; 92(4): 546–549
64.
EcotièreLThierryADebiais-DelpechCet al.Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients. Nephrol Dial Transplant2016; 31(1): 64–72
65.
CohenCRoyerBJavaugueVet al.Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int2015; 88(5): 1135–1143
